Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

Trial Profile

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 28 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 18 Oct 2018 Planned initiation date changed from 14 Sep 2018 to 17 Oct 2018.
    • 06 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top